Targeting c-Mpl for revival of human immunodeficiency virus type 1-induced hematopoietic inhibition when CD34+ progenitor cells are re-engrafted into a fresh stromal microenvironment in vivo.
Koka
Prasad S
PS
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, 23-120 CHS, 10833 Le Conte Avenue, Los Angeles, CA 90095-1735. pkoka@ucla.edu
Kitchen
Christina M R
CM
Reddy
Srinivasa T
ST
D000818:Animals; D018952:Antigens, CD34 / Q000378:metabolism*; D002454:Cell Differentiation; D019070:Cell Lineage; D003114:Colony-Forming Units Assay; D015658:HIV Infections / Q000473:pathology; D015497:HIV-1 / Q000472:pathogenicity* / Q000502:physiology; D006410:Hematopoiesis / Q000502:physiology*; D006801:Humans; D016031:Liver Transplantation; D051379:Mice; D016513:Mice, SCID; D009363:Neoplasm Proteins / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D018121:Receptors, Cytokine / Q000378:metabolism*; D053628:Receptors, Thrombopoietin; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000166:cytology / Q000502:physiology*; D013950:Thymus Gland / Q000637:transplantation
D018952:Antigens, CD34; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human